M. Kuperminc

Phase II trials of baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5‐fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer

R. Gelman, D. Tormey, F. Cummings, 1981, Cancer.

A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma

J. Wolter, J. Ruckdeschel, J. Arseneau, 2004, Investigational New Drugs.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

E Harrison, H. Burger, G. Batist, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163)

G. Wampler, W. Regelson, M. Kuperminc, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study of tilorone, a non-marrow depressing antitumor agent.

G. Wampler, W. Regelson, M. Kuperminc, 1973, Cancer chemotherapy reports.

Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer.

G. Wampler, W. Regelson, S. J. Mellette, 1972, Cancer chemotherapy reports.

Nephrotoxicity of lomustine

R. Weiss, M. Kuperminc, M. Ellis, 1985, Cancer Chemotherapy and Pharmacology.

Chemotherapy of malignant mesothelioma

G. Wampler, W. Regelson, J. Mellette, 1977, Cancer.